Citations 1
Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
O’Neil, Bert H. , Starodub, Alexander, Jonker, Derek J. , Edenfield, William J. , El‐Rayes, Bassel F. , Hálfdánarson, Þorvarður R. , Ramanathan, Ramesh K., Pitot, Henry C., Britten, Carolyn D., Adesunloye, Bamidele, Borodyansky, Laura, Li, Chiang, El-Rayes, Bassel F , Halfdanarson, Thorvardur R , Hubbard, Joleen M. , Grothey, Axel
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 3564-3564
